Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  implantable cardioverter-defibrillator
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Cardiac complications during DLBCL treatment using R-CHOP

100%
Sosnowska-Pasiarska B., Zgódka P., Steckiewicz P., Pasiarski M.
|
2019
|
vol. 9
|
issue 1
22-26
EN
Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.
2
Publication available in full text mode
Content available

“Life-saving” inappropriate implantable cardioverter-defibrillator shocks in a cancer patient

100%
Futyma P., Płoszczyca M., Głuszczyk R., Kuźniar J.
OncoReview
|
2016
|
vol. 6
|
issue 3
A118-121
EN
Impaired left ventricular ejection fraction (LVEF) in patients with cancer can disqualify them from targeted antineoplastic treatment. We present the case of 63-year-old male with gastric cancer treated palliatively, with concomitant dilated cardiomyopathy, atrial fibrillation (AF) and after implantation of a cardioverter-defibrillator (ICD), in whom inappropriate ICD discharges caused unexpected return of sinus rhythm and significant LVEF improvement, what subsequently led to reclassification to targeted chemotherapy. In conclusion, unexpected return of sinus rhythm in cancer patients with AF and reduced LVEF may lead to LVEF recovery and enable the use of antineoplastic treatment with improved prognosis.
3
Publication available in full text mode
Content available

Radiotherapy in patients with cardiac implantable electronic devices – clinical experience

88%
Blamek S.
OncoReview
|
2017
|
vol. 7
|
issue 2
64-69
EN
The number of patients with cardiac implantable electronic devices (CIEDs) constantly increases and due to growing incidence of cancer, many of them will require an anticancer treatment. At least a half of patients treated for malignant neoplasms, apart from other treatment methods, require radiotherapy. Although papers presenting the results of in vitro studies provide clues on the susceptibility of CIEDs to ionizing radiation, the research methods used often stand out from typical clinical situations. Direct irradiation of the devices is avoided and the doses delivered to pulse generators are far below those seen in the in vitro studies. In this review the most important clinical observations made during irradiation of patients with CIEDs are summarized and practical directions for physicians and physicists involved in radiation treatment planning and delivery are given.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.